BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers

Reuters

31 Mar

BRIEF-Keros <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers

March 31 (Reuters) - Keros Therapeutics Inc KROS.O:

KEROS THERAPEUTICS ANNOUNCES INITIAL TOPLINE RESULTS FROM PHASE 1 CLINICAL TRIAL OF KER-065 IN HEALTHY VOLUNTEERS
KEROS THERAPEUTICS INC -PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD, SUBJECT TO POSITIVE REGULATORY INTERACTION
KEROS THERAPEUTICS INC: PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD
KEROS THERAPEUTICS INC: KER-065 WAS GENERALLY WELL-TOLERATED, WITH NO MAJOR SAFETY SIGNALS OBSERVED TO DATE
KEROS THERAPEUTICS: TO INITIATE PHASE 2 CLINICAL TRIAL OF KER-065 IN PATIENTS WITH DMD IN Q1 2026

Source text: ID:nGNX1XjyDG

Further company coverage: KROS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2523077916"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2523077916\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2523077916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523077916","market":"nz","top_or_hot":-1,"title":"BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers</title></head><body><p><span>March 31 (Reuters)</span><span> - </span>Keros Therapeutics Inc <span>KROS.O</span>:</p><ul><li><p>KEROS THERAPEUTICS ANNOUNCES INITIAL TOPLINE RESULTS FROM PHASE 1 CLINICAL TRIAL OF KER-065 IN HEALTHY VOLUNTEERS</p></li><li><p>KEROS THERAPEUTICS INC -PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD, SUBJECT TO POSITIVE REGULATORY INTERACTION</p></li><li><p>KEROS THERAPEUTICS INC: PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD</p></li><li><p>KEROS THERAPEUTICS INC: KER-065 WAS GENERALLY WELL-TOLERATED, WITH NO MAJOR SAFETY SIGNALS OBSERVED TO DATE</p></li><li><p>KEROS THERAPEUTICS: TO INITIATE PHASE 2 CLINICAL TRIAL OF KER-065 IN PATIENTS WITH DMD IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX1XjyDG</span></p><p>Further company coverage: <span>KROS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-31 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy Volunteers</title></head><body><p><span>March 31 (Reuters)</span><span> - </span>Keros Therapeutics Inc <span>KROS.O</span>:</p><ul><li><p>KEROS THERAPEUTICS ANNOUNCES INITIAL TOPLINE RESULTS FROM PHASE 1 CLINICAL TRIAL OF KER-065 IN HEALTHY VOLUNTEERS</p></li><li><p>KEROS THERAPEUTICS INC -PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD, SUBJECT TO POSITIVE REGULATORY INTERACTION</p></li><li><p>KEROS THERAPEUTICS INC: PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD</p></li><li><p>KEROS THERAPEUTICS INC: KER-065 WAS GENERALLY WELL-TOLERATED, WITH NO MAJOR SAFETY SIGNALS OBSERVED TO DATE</p></li><li><p>KEROS THERAPEUTICS: TO INITIATE PHASE 2 CLINICAL TRIAL OF KER-065 IN PATIENTS WITH DMD IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX1XjyDG</span></p><p>Further company coverage: <span>KROS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KROS","symbol_name":"Keros Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC02F:1","article_id":"2523077916","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523077916","pubTimestamp":1743415472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy VolunteersMarch 31 (Reuters) - Keros Therapeutics Inc KROS.O:KEROS THERAPEUTICS ANNOUNCES I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KROS":"Keros Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Keros Therapeutics宣布KER-065在健康志愿者中进行的1期临床试验的初步顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KROS":0.9},"content_text":"BRIEF-Keros Therapeutics Announces Initial Topline Results From Phase 1 Clinical Trial Of KER-065 In Healthy VolunteersMarch 31 (Reuters) - Keros Therapeutics Inc KROS.O:KEROS THERAPEUTICS ANNOUNCES INITIAL TOPLINE RESULTS FROM PHASE 1 CLINICAL TRIAL OF KER-065 IN HEALTHY VOLUNTEERSKEROS THERAPEUTICS INC -PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMD, SUBJECT TO POSITIVE REGULATORY INTERACTIONKEROS THERAPEUTICS INC: PLANS ON ADVANCING KER-065 INTO A PHASE 2 CLINICAL TRIAL IN DMDKEROS THERAPEUTICS INC: KER-065 WAS GENERALLY WELL-TOLERATED, WITH NO MAJOR SAFETY SIGNALS OBSERVED TO DATEKEROS THERAPEUTICS: TO INITIATE PHASE 2 CLINICAL TRIAL OF KER-065 IN PATIENTS WITH DMD IN Q1 2026Source text: ID:nGNX1XjyDGFurther company coverage: KROS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}